Martin Silverman, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Silverman’s office at (408) 356-0431 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G63938 · Current
Licensed to practise in California · since 1988 · expires 2027-11-30 · University of South Florida College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Silicon Valley Surgery Center, LPAmbulatory Surgery Center · Campbell, CA.78 owner since 1999 · accredited by AAAHCAccreditation Renewed4 inspections, 1 with deficiencies · last 2024-09-16
- Silicon Valley Surgery Center, LP - BascomAmbulatory Surgery Center · Campbell, CA.78 owner since 1999 · accredited by AAAHCAccreditation RenewedNo inspections published
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$22,400
Medicare paid this office $22,400 for 151 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 45 | $5,792 | $84 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 96 | $4,599 | $48 |
| Return visit (30+ min) | 30 | $4,065 | $104 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 63 | $3,619 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,643 | $110 |
See all 6 services
| Short return visit (20+ min) | 45 | $5,792 | $84 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 96 | $4,599 | $48 |
| Return visit (30+ min) | 30 | $4,065 | $104 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 63 | $3,619 | $57 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,643 | $110 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $735 | $14 |
Who their Medicare patients are
151 Original Medicare patients in 2024. Average age 75 · Women 100% · Also on Medicaid 0% · Health risk score 0.75. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 56% · Cancer 17% · Coronary heart disease 15% · Atrial fibrillation 13% · Diabetes 12% · Depression 11% · Heart failure 7% · Chronic kidney disease 7%.
The office billed $81,384, Medicare allowed $27,758 and paid $22,400; for 368 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 151 | 368 | 75 | 0.75 | $81,384 | $22,400 |
| 2023 | 188 | 424 | 75 | 0.89 | $109,066 | $29,425 |
| 2022 | 207 | 471 | 74 | 0.78 | $114,404 | $31,717 |
| 2021 | 222 | 568 | 73 | 0.72 | $150,011 | $39,915 |
| 2020 | 178 | 489 | 74 | 0.81 | $125,604 | $29,512 |
| 2019 | 160 | 407 | 74 | 0.83 | $105,838 | $23,653 |
| 2018 | 197 | 510 | 73 | 0.83 | $117,847 | $28,412 |
| 2017 | 122 | 308 | 73 | 0.83 | $64,510 | $16,246 |
| 2016 | 190 | 498 | 73 | 0.70 | $102,102 | $26,137 |
| 2015 | 201 | 634 | 73 | 0.74 | $92,404 | $33,042 |
| 2014 | 229 | 716 | 73 | 0.69 | $66,295 | $37,642 |
| 2013 | 195 | 545 | 72 | 0.70 | $60,639 | $29,464 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Short return visit (20+ min) | 65 | $7,000 | $76 |
| Return visit (30+ min) | 44 | $6,270 | $114 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 102 | $4,875 | $48 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 22 | $3,349 | $120 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | $2,794 | $56 |
| Smear for infectious agents | 12 | $74 | $6 |
| Tissue fungi or parasites | 11 | $46 | $4 |
| Automated urinalysis test | 13 | $31 | $2 |
2022: 10 services
| Return visit (30+ min) | 69 | $8,780 | $105 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 103 | $4,916 | $48 |
| Short return visit (20+ min) | 49 | $4,718 | $79 |
| New patient visit (45+ min) | 23 | $3,092 | $134 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 53 | $2,919 | $55 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $2,089 | $110 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 28 | $500 | $18 |
| Administration of influenza virus vaccine | 12 | $449 | $37 |
| Automated urinalysis test | 28 | $64 | $2 |
| Smear for infectious agents | 11 | $63 | $6 |
2021: 11 services
| Return visit (30+ min) | 66 | $9,776 | $119 |
| Short return visit (20+ min) | 47 | $7,115 | $84 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 112 | $5,512 | $49 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 72 | $4,074 | $57 |
| New patient visit (45+ min) | 25 | $3,929 | $157 |
| Complete ultrasound scan of pelvis | 14 | $1,878 | $110 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,825 | $122 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 58 | $1,047 | $18 |
| Administration of influenza virus vaccine | 11 | $240 | $22 |
| Smear for infectious agents | 15 | $87 | $6 |
| Automated urinalysis test | 18 | $45 | $2 |
2020: 8 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 114 | $5,592 | $49 |
| Return visit (30+ min) | 42 | $5,366 | $99 |
| Short return visit (20+ min) | 35 | $3,975 | $67 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 66 | $3,675 | $56 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $3,037 | $127 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 90 | $1,616 | $18 |
| Influenza vaccine split virus, preservative free | 17 | $1,031 | $61 |
| Administration of influenza virus vaccine | 18 | $376 | $21 |
2019: 6 services
| Short return visit (20+ min) | 49 | $5,391 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 93 | $4,414 | $47 |
| Return visit (30+ min) | 35 | $4,191 | $105 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $3,317 | $114 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 58 | $3,185 | $55 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 74 | $1,309 | $18 |
2018: 6 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 113 | $6,063 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 112 | $4,953 | $44 |
| Return visit (30+ min) | 38 | $4,579 | $95 |
| Short return visit (20+ min) | 53 | $4,445 | $59 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $2,941 | $118 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 100 | $1,925 | $19 |
2017: 6 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 65 | $3,612 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 72 | $3,307 | $46 |
| Return visit (30+ min) | 25 | $2,533 | $94 |
| Short return visit (20+ min) | 27 | $2,266 | $61 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,510 | $116 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 61 | $1,304 | $21 |
2016: 6 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 106 | $5,868 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 114 | $5,166 | $45 |
| Short return visit (20+ min) | 64 | $4,975 | $59 |
| Return visit (30+ min) | 33 | $3,513 | $92 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $2,385 | $104 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 93 | $1,975 | $21 |
2015: 7 services
| Short return visit (20+ min) | 101 | $7,988 | $58 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 103 | $5,621 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 114 | $5,080 | $45 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 138 | $2,886 | $21 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 20 | $2,814 | $122 |
| Return visit (30+ min) | 20 | $2,025 | $96 |
| Dxa bone density measurement of hip, pelvis, spine | 36 | $1,886 | $52 |
2014: 11 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 142 | $7,654 | $54 |
| Short return visit (20+ min) | 92 | $7,543 | $62 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 141 | $6,334 | $45 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 24 | $3,471 | $124 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 139 | $2,957 | $21 |
| Dxa bone density measurement of hip, pelvis, spine | 38 | $2,378 | $63 |
| Long return visit (40+ min) | 12 | $1,485 | $124 |
| New patient visit (45+ min) | 11 | $1,439 | $131 |
| Return visit (30+ min) | 13 | $1,401 | $93 |
| Short return visit | 16 | $498 | $31 |
| Manual urinalysis test with examination using microscope, non-automated | 15 | $63 | $4 |
2013: 9 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 89 | $4,818 | $54 |
| Short return visit (20+ min) | 62 | $4,408 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 94 | $4,268 | $45 |
| New patient visit (45+ min) | 22 | $2,634 | $120 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 28 | $2,344 | $69 |
| Short return visit | 55 | $2,104 | $35 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 85 | $1,829 | $22 |
| Return visit (30+ min) | 13 | $1,203 | $93 |
| Dxa bone density measurement of hip, pelvis, spine | 17 | $1,151 | $64 |
Drugs they prescribed that Part D paid
$49,585
Pharmacies billed $49,585 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 276) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
212 generic and 64 brand-name prescriptions · $49,585 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 14 | $7,347 | $525 |
| Estradiol | 71 | $4,999 | $70 |
| Yuvafem | 21 | $4,473 | $213 |
| Progesterone | 24 | $1,047 | $44 |
| Raloxifene | 11 | $833 | $76 |
See all 6 drugs
| Estring | 14 | $7,347 | $525 |
| Estradiol | 71 | $4,999 | $70 |
| Yuvafem | 21 | $4,473 | $213 |
| Progesterone | 24 | $1,047 | $44 |
| Raloxifene | 11 | $833 | $76 |
| Valacyclovir | 16 | $205 | $13 |
Year by year
| 2024 | 276 | 78 | 0% (0) | 23% | $49,585 |
| 2023 | 336 | 115 | 0% (0) | None | $61,466 |
| 2022 | 311 | 114 | 0% (0) | 31% | $50,341 |
| 2021 | 345 | 109 | 0% (0) | 23% | $55,502 |
| 2020 | 342 | 92 | 0% (0) | 22% | $49,922 |
| 2019 | 303 | 79 | None | 24% | $46,999 |
| 2018 | 250 | 77 | 0% (0) | 30% | $39,965 |
| 2017 | 200 | 66 | 0% (0) | 26% | $23,816 |
| 2016 | 324 | 82 | 0% (0) | 42% | $44,322 |
| 2015 | 342 | 86 | 0% (0) | 49% | $45,478 |
| 2014 | 360 | 85 | None | 46% | $38,306 |
| 2013 | 392 | 84 | None | 49% | $42,558 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Estradiol | 70 | $8,739 | $125 |
| Imvexxy | 15 | $8,546 | $570 |
| Estring | 15 | $8,511 | $567 |
| Yuvafem | 31 | $7,941 | $256 |
| Raloxifene | 13 | $1,491 | $115 |
| Progesterone | 11 | $598 | $54 |
| Clobetasol Propionate | 12 | $545 | $45 |
| Nitrofurantoin Mono-Macro | 14 | $270 | $19 |
| Alendronate | 20 | $261 | $13 |
| Clotrimazole-Betamethasone | 12 | $248 | $21 |
| Zolpidem | 12 | $157 | $13 |
2022: 9 drugs
| Estring | 18 | $9,729 | $540 |
| Yuvafem | 32 | $6,675 | $209 |
| Imvexxy | 11 | $6,321 | $575 |
| Estradiol | 62 | $5,703 | $92 |
| Raloxifene | 12 | $1,425 | $119 |
| Progesterone | 11 | $834 | $76 |
| Clobetasol Propionate | 12 | $695 | $58 |
| Nitrofurantoin Mono-Macro | 24 | $277 | $12 |
| Alendronate | 19 | $203 | $11 |
2021: 8 drugs
| Estradiol | 84 | $9,768 | $116 |
| Yuvafem | 35 | $7,063 | $202 |
| Estring | 12 | $6,251 | $521 |
| Myrbetriq | 11 | $4,764 | $433 |
| Minivelle | 11 | $2,189 | $199 |
| Clobetasol Propionate | 13 | $1,456 | $112 |
| Medroxyprogesterone Acetate | 13 | $201 | $15 |
| Alendronate | 16 | $198 | $12 |
2020: 6 drugs
| Estradiol | 104 | $12,095 | $116 |
| Prometrium | 21 | $8,120 | $387 |
| Yuvafem | 36 | $7,150 | $199 |
| Alendronate | 19 | $265 | $14 |
| Medroxyprogesterone Acetate | 15 | $211 | $14 |
| Zolpidem | 11 | $110 | $10 |
2019: 6 drugs
| Prometrium | 19 | $10,799 | $568 |
| Estradiol | 100 | $10,709 | $107 |
| Estring | 12 | $5,290 | $441 |
| Yuvafem | 23 | $3,275 | $142 |
| Combipatch | 14 | $2,601 | $186 |
| Alendronate | 14 | $163 | $12 |
2018: 6 drugs
| Yuvafem | 30 | $9,064 | $302 |
| Premarin | 24 | $8,020 | $334 |
| Estradiol | 63 | $6,303 | $100 |
| Combipatch | 14 | $2,372 | $169 |
| Progesterone | 17 | $1,445 | $85 |
| Medroxyprogesterone Acetate | 11 | $175 | $16 |
2017: 3 drugs
| Yuvafem | 21 | $5,256 | $250 |
| Premarin | 19 | $4,981 | $262 |
| Estradiol | 49 | $1,702 | $35 |
2016: 10 drugs
| Vagifem | 34 | $10,902 | $321 |
| Premarin | 25 | $6,330 | $253 |
| Estrace | 15 | $3,864 | $258 |
| Estring | 12 | $3,859 | $322 |
| Prometrium | 13 | $2,123 | $163 |
| Estradiol | 56 | $1,847 | $33 |
| Clobetasol Propionate | 11 | $1,099 | $100 |
| Nitrofurantoin Mono-Macro | 13 | $287 | $22 |
| Medroxyprogesterone Acetate | 22 | $145 | $7 |
| Sertraline | 11 | $90 | $8 |
2015: 8 drugs
| Vagifem | 39 | $11,999 | $308 |
| Premarin | 53 | $8,492 | $160 |
| Estrace | 14 | $5,114 | $365 |
| Estradiol | 65 | $2,378 | $37 |
| Prometrium | 12 | $1,110 | $92 |
| Valacyclovir | 16 | $557 | $35 |
| Synthroid | 12 | $349 | $29 |
| Medroxyprogesterone Acetate | 17 | $138 | $8 |
2014: 11 drugs
| Premarin | 41 | $7,590 | $185 |
| Vagifem | 31 | $7,106 | $229 |
| Estradiol | 71 | $2,817 | $40 |
| Estrace | 11 | $1,845 | $168 |
| Prometrium | 11 | $874 | $79 |
| Progesterone | 13 | $652 | $50 |
| Synthroid | 12 | $561 | $47 |
| Oxybutynin Chloride Er | 12 | $366 | $31 |
| Terconazole | 11 | $351 | $32 |
| Nitrofurantoin Mono-Macro | 11 | $344 | $31 |
| Medroxyprogesterone Acetate | 18 | $168 | $9 |
2013: 10 drugs
| Vagifem | 40 | $7,857 | $196 |
| Premarin | 48 | $6,860 | $143 |
| Vesicare | 19 | $5,717 | $301 |
| Estradiol | 61 | $2,373 | $39 |
| Estrace | 12 | $1,640 | $137 |
| Valacyclovir | 13 | $770 | $59 |
| Oxybutynin Chloride Er | 14 | $706 | $50 |
| Synthroid | 17 | $468 | $28 |
| Terconazole | 11 | $314 | $29 |
| Ciprofloxacin | 11 | $49 | $4 |
Money from drug and device companies
$85 in 2024
| 2024 | 2 | 10 | None | $85 |
| 2023 | 1 | 7 | None | $50 |
| 2021 | 2 | 2 | None | $39 |
| 2020 | 3 | 10 | None | $282 |
| 2019 | 5 | 16 | None | $289 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | None | $61 | 9 payments
|
| Hologic Sales and Service | Aptima | $25 | 1 payment
|
See all 10 published payments
| Hologic Sales and Service | Meals · 2024-08-13 | Aptima | $25 |
| Mayne Pharma Commercial | Meals · 2024-08-13 | None | $8 |
| Mayne Pharma Commercial | Meals · 2024-07-23 | None | $7 |
| Mayne Pharma Commercial | Meals · 2024-07-18 | None | $6 |
| Mayne Pharma Commercial | Meals · 2024-07-08 | None | $6 |
| Mayne Pharma Commercial | Meals · 2024-05-06 | None | $7 |
| Mayne Pharma Commercial | Meals · 2024-04-01 | None | $7 |
| Mayne Pharma Commercial | Meals · 2024-03-11 | None | $6 |
| Mayne Pharma Commercial | Meals · 2024-02-05 | None | $7 |
| Mayne Pharma Commercial | Meals · 2024-01-16 | None | $5 |
See earlier years (2023, 2021, 2020, 2019)
2023: $50
| Mayne Pharma Commercial | None | $50 | 7 payments
|
2021: $39
| AbbVie | Lo Loestrin Fe | $22 | 1 payment
|
| Myovant Sciences | Myfembree | $18 | 1 payment
|
2020: $282
| AbbVie | Orilissa | $259 | 8 payments
|
| Allergan | Lo Loestrin Fe | $12 | 1 payment
|
| TherapeuticsMD | Annovera | $11 | 1 payment
|
2019: $289
| AbbVie | Orilissa | $208 | 10 payments
|
| Allergan | Lo Loestrin Fe | $26 | 2 payments
|
| TherapeuticsMD | Imvexxy | $25 | 2 payments
|
| Exeltis USA | Slynd | $19 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $11 | 1 payment
|
Professional record
- NPI
- 1376508127
- Licence
- CA G63938California G63938: Current · expires 2027-11-30
- Trained
- University of South Florida College of Medicine, 1987
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 15151 National Ave, Los Gatos, CA, 95032
- NPI first listed
- 2006-04-17
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.